Characteristics of patients with vulvar, cervical, ovarian, and endometrial cancer who were actively working at the time of diagnosis, reported to MarketScan, diagnosed between 2009 and 2017 and followed through 2018
| Characteristics | Vulvar cancer | Cervical cancer | Ovarian cancer | Endometrial cancer | ||||||||
| EC (n=30) | No EC (n=161) | P* | EC (n=194) | No EC (n=747) | P* | EC (n=383) | No EC (n=1456) | P* | EC (n=972) | No EC (n=3503) | P* | |
| Age at diagnosis, n (%) | 0.4 | 0.4 | <0.001 | <0.001 | ||||||||
| 44 or less | 4 (13.3) | 25 (15.5) | 100 (51.5) | 426 (57.0) | 76 (19.8) | 388 (26.6) | 121 (12.4) | 473 (13.5) | ||||
| 45 to 49 | 6 (20.0) | 33 (20.5) | 31 (16.0) | 126 (16.9) | 59 (15.4) | 241 (16.6) | 103 (10.6) | 439 (12.5) | ||||
| 50 to 53 | 3 (10.0) | 38 (23.6) | 19 (9.8) | 66 (8.8) | 55 (14.4) | 255 (17.5) | 121 (12.4) | 619 (17.7) | ||||
| 54 to 57 | 8 (26.7) | 29 (18.0) | 19 (9.8) | 49 (6.6) | 78 (20.4) | 274 (18.8) | 250 (25.7) | 904 (25.8) | ||||
| 58 to 63 | 9 (30.0) | 36 (22.4) | 25 (12.9) | 80 (10.7) | 115 (30.0) | 298 (20.5) | ||||||
| Health insurance plan type, n (%) | 0.4 | 0.644 | 0.9 | <0.001 | ||||||||
| HMO | 5 (16.7) | 15 (9.3) | 24 (12.4) | 111 (14.9) | 64 (16.7) | 227 (15.6) | 131 (13.5) | 553 (15.8) | ||||
| PPO | 16 (53.3) | 101 (62.7) | 106 (54.6) | 405 (54.2) | 208 (54.3) | 806 (55.4) | 508 (52.3) | 2008 (57.3) | ||||
| Other† | 9 (30.0) | 45 (28.0) | 64 (33.0) | 231 (30.9) | 111 (29.0) | 423 (29.1) | 333 (34.3) | 942 (26.9) | ||||
| Region, n (%) | 0.002 | 0.7 | <0.001 | <0.001 | ||||||||
| Northeast | 5 (16.7) | 23 (14.3) | 34 (17.5) | 112 (15.0) | 61 (15.9) | 254 (17.4) | 186 (19.1) | 615 (17.6) | ||||
| North central | 16 (53.3) | 35 (21.7) | 45 (23.2) | 158 (21.2) | 71 (18.5) | 270 (18.5) | 274 (28.2) | 791 (22.6) | ||||
| South | 6 (20.0) | 81 (50.3) | 79 (40.7) | 338 (45.2) | 140 (36.6) | 659 (45.3) | 299 (30.8) | 1454 (41.5) | ||||
| West | 3 (10.0) | 22 (13.7) | 36 (18.6) | 138 (18.5) | 111 (29.0) | 271 (18.6) | 212 (21.8) | 639 (18.2) | ||||
| Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 2 (0.1) | 1 (0.1) | 4 (0.1) | ||||
| Charlson Comorbidity Index score, n (%) | 0.6 | <0.001 | 0.7 | 0.2 | ||||||||
| 0 | 26 (86.7) | 144 (89.4) | 174 (89.7) | 717 (96.0) | 348 (90.9) | 1332 (91.5) | 806 (82.9) | 2965 (84.6) | ||||
| 1+ | 4 (13.3) | 17 (10.6) | 20 (10.3) | 30 (4.0) | 35 (9.1) | 124 (8.5) | 166 (17.1) | 538 (15.4) | ||||
| Metastatic status, n (%)‡ | 0.9 | 0.003 | <0.001 | 0 | ||||||||
| Non-metastatic | 27 (90.0) | 146 (90.7) | 150 (77.3) | 643 (86.1) | 178 (46.5) | 922 (63.3) | 853 (87.8) | 3188 (91.0) | ||||
| Metastatic | 3 (10.0) | 15 (9.3) | 44 (22.7) | 104 (13.9) | 205 (53.5) | 534 (36.7) | 119 (12.2) | 315 (9.0) | ||||
| Treatment group, n (%) | 0.9 | 0.2 | <0.001 | <0.001 | ||||||||
| Surgery only | 26 (86.7) | 136 (84.5) | 111 (57.2) | 476 (63.7) | 99 (25.8) | 662 (45.5) | 755 (77.7) | 2904 (82.9) | ||||
| Surgery with adjuvant treatment | 4 (13.3) | 24 (14.9) | 50 (25.8) | 154 (20.6) | 244 (63.7) | 708 (48.6) | 202 (20.8) | 550 (15.7) | ||||
| Chemotherapy, radiation, or chemoradiation only | 0 (0.0) | 1 (0.6) | 33 (17.0) | 117 (15.7) | 40 (10.4) | 86 (5.9) | 15 (1.5) | 49 (1.4) | ||||
| Adverse events, n (%) | 0.2 | 0.4 | 0.04 | 0.7 | ||||||||
| None | 28 (93.3) | 127 (78.9) | 177 (91.2) | 659 (88.2) | 264 (68.9) | 1094 (75.1) | 814 (83.7) | 2972 (84.8) | ||||
| 1 | 2 (6.7) | 33 (20.5) | 14 (7.2) | 78 (10.4) | 106 (27.7) | 315 (21.6) | 140 (14.4) | 474 (13.5) | ||||
| 2+ | 0 (0.0) | 1 (0.6) | 3 (1.5) | 10 (1.3) | 13 (3.4) | 47 (3.2) | 18 (1.9) | 57 (1.6) | ||||
| Year of diagnosis, n (%) | 0.5 | 0.8 | 0.031 | 0.2 | ||||||||
| 2009 | 4 (13.3) | 14 (8.7) | 14 (7.2) | 67 (9.0) | 22 (5.7) | 122 (8.4) | 90 (9.3) | 296 (8.4) | ||||
| 2010 | 3 (10.0) | 10 (6.2) | 14 (7.2) | 76 (10.2) | 33 (8.6) | 126 (8.7) | 80 (8.2) | 339 (9.7) | ||||
| 2011 | 0 (0.0) | 11 (6.8) | 15 (7.7) | 61 (8.2) | 35 (9.1) | 149 (10.2) | 101 (10.4) | 357 (10.2) | ||||
| 2012 | 5 (16.7) | 17 (10.6) | 20 (10.3) | 64 (8.6) | 30 (7.8) | 150 (10.3) | 92 (9.5) | 384 (11.0) | ||||
| 2013 | 1 (3.3) | 18 (11.2) | 17 (8.8) | 68 (9.1) | 32 (8.4) | 115 (7.9) | 96 (9.9) | 358 (10.2) | ||||
| 2014 | 2 (6.7) | 16 (9.9) | 17 (8.8) | 72 (9.6) | 18 (4.7) | 120 (8.2) | 81 (8.3) | 363 (10.4) | ||||
| 2015 | 5 (16.7) | 14 (8.7) | 33 (17.0) | 98 (13.1) | 41 (10.7) | 154 (10.6) | 126 (13.0) | 428 (12.2) | ||||
| 2016 | 4 (13.3) | 27 (16.8) | 35 (18.0) | 123 (16.5) | 87 (22.7) | 260 (17.9) | 165 (17.0) | 515 (14.7) | ||||
| 2017 | 6 (20.0) | 34 (21.1) | 29 (14.9) | 118 (15.8) | 85 (22.2) | 260 (17.9) | 141 (14.5) | 463 (13.2) | ||||
*P values were derived using the χ2 test or Fisher’s exact test when appropriate.
†Other health insurance plans include comprehensive, point-of-service, point-of-service with capitation, high-deductible, and exclusive-provider-organization health plans.
‡Metastatic status was derived using ICD 9/ICD 10 codes.
EC, employment change; HMO, health maintenance organization; ICD 9/ICD 10, International Classification of Diseases 9th and 10th editions; PPO, preferred provider organization.